Pluristem Therapeutics (PSTI) Gains Following Positive PLX-PAD Cells Preclinical Data in DMD
Tweet Send to a Friend
Pluristem Therapeutics (NASDAQ: PSTI) is gaining 11.6% ion pre-open trade after the company reported ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
